Benzinga | Jan 14, 2022 04:50PM EST

Gilead Issues Statement On Zydelig U.S. Indication For Follicular Lymphoma And Small Lymphocytic Leukemia; Says Working With FDA To Complete Withdrawal Of FL, SLL Indications In U.S.

https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-zydelig-us-indication-for-follicular-lymphoma-and-small-lymphocytic-leukemia